Latigo Biotherapeutics' IPO, priced at the top of its $16–$18 range with an upsized 19.2 million shares at $18 on August 6, 2026, for $345.6 million in gross proceeds, drives the market's tight clustering around $1.3B–$1.45B outcomes. Strong demand for its oral NaV1.8 inhibitor pipeline targeting acute and chronic pain, ahead of Phase 3 trials and potential FDA submission, underpins the $1.45B+ leading probability at 53.5%. This reflects broader 2026 biotech IPO momentum and pre-IPO financing of roughly $288–322 million, which positions the company for a post-IPO market cap above the targeted $1.08 billion valuation. Traders weigh these catalysts against typical post-IPO volatility and execution risks on upcoming clinical milestones.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于8.5亿-10亿美元 15%
低于8.5亿美元 7%
2026年10月前不上市 1.5%
10亿美元-11.5亿美元 0
最新
最新
2026-08-07
低于8.5亿美元
9%
8.5亿-10亿美元
25%
10亿美元-11.5亿美元
33%
11.5亿美元-13亿美元
36%
13亿-14.5亿美元
52%
14.5亿美元+
54%
2026年10月前不上市
2%
8.5亿-10亿美元 15%
低于8.5亿美元 7%
2026年10月前不上市 1.5%
10亿美元-11.5亿美元 0
最新
最新
2026-08-07
低于8.5亿美元
$80 交易量
9%
8.5亿-10亿美元
$211 交易量
25%
10亿美元-11.5亿美元
$111 交易量
33%
11.5亿美元-13亿美元
$86 交易量
36%
13亿-14.5亿美元
$45 交易量
52%
14.5亿美元+
$75 交易量
54%
2026年10月前不上市
$167 交易量
2%
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics' IPO, priced at the top of its $16–$18 range with an upsized 19.2 million shares at $18 on August 6, 2026, for $345.6 million in gross proceeds, drives the market's tight clustering around $1.3B–$1.45B outcomes. Strong demand for its oral NaV1.8 inhibitor pipeline targeting acute and chronic pain, ahead of Phase 3 trials and potential FDA submission, underpins the $1.45B+ leading probability at 53.5%. This reflects broader 2026 biotech IPO momentum and pre-IPO financing of roughly $288–322 million, which positions the company for a post-IPO market cap above the targeted $1.08 billion valuation. Traders weigh these catalysts against typical post-IPO volatility and execution risks on upcoming clinical milestones.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
市场开放时间： Aug 5, 2026, 5:52 AM ET
交易量
$775结束日期
2026-08-07市场开放时间
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics' IPO, priced at the top of its $16–$18 range with an upsized 19.2 million shares at $18 on August 6, 2026, for $345.6 million in gross proceeds, drives the market's tight clustering around $1.3B–$1.45B outcomes. Strong demand for its oral NaV1.8 inhibitor pipeline targeting acute and chronic pain, ahead of Phase 3 trials and potential FDA submission, underpins the $1.45B+ leading probability at 53.5%. This reflects broader 2026 biotech IPO momentum and pre-IPO financing of roughly $288–322 million, which positions the company for a post-IPO market cap above the targeted $1.08 billion valuation. Traders weigh these catalysts against typical post-IPO volatility and execution risks on upcoming clinical milestones.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
交易量
$775结束日期
2026-08-07市场开放时间
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...Latigo Biotherapeutics' IPO, priced at the top of its $16–$18 range with an upsized 19.2 million shares at $18 on August 6, 2026, for $345.6 million in gross proceeds, drives the market's tight clustering around $1.3B–$1.45B outcomes. Strong demand for its oral NaV1.8 inhibitor pipeline targeting acute and chronic pain, ahead of Phase 3 trials and potential FDA submission, underpins the $1.45B+ leading probability at 53.5%. This reflects broader 2026 biotech IPO momentum and pre-IPO financing of roughly $288–322 million, which positions the company for a post-IPO market cap above the targeted $1.08 billion valuation. Traders weigh these catalysts against typical post-IPO volatility and execution risks on upcoming clinical milestones.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题